Verona Pharma plc — Director's Dealing 2025

May 16, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2025-05-14

Reporting Person: ACKERMANN CHRISTINA (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-14	Ordinary Shares	M	40000	$1.9338	Acquired	81880	Direct
2025-05-14	Ordinary Shares	S	40000	$8.44	Disposed	41880	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-14	Share Options (Right to Buy)	$1.9338	M	40000	Disposed	2034-04-28	Ordinary Shares (40000)	Direct

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into on February 12, 2025.

F3: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $8.3894 to $8.5688 per Ordinary Share, inclusive (or $67.115 to $68.55 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F4: Consists of 41,880 Ordinary Shares represented by 5,235 ADSs.

F5: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.

F6: The option is fully vested.